NCT02113241View on ClinicalTrials.gov

Effect of Dapagliflozin Administration on Metabolic Syndrome, Insulin Sensitivity, and Insulin Secretion

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

April 30, 2014

Primary Completion Date

May 31, 2015

Study Completion Date

May 31, 2015

Conditions
Metabolic Syndrome X
Interventions
DRUG

Dapagliflozin

Dapagliflozin capsules, 10 mg, one per day before breakfast during 90 days.

DRUG

Placebo

Placebo capsules, 10 mg, one per day before breakfast during 90 days.

Trial Locations (1)

44340

Instituto de Terapeútica Experimental y Clínica. Centro Universitario de Ciencias de la Salud. Universidad de Guadalajara, Guadalajara

All Listed Sponsors
lead

University of Guadalajara

OTHER

NCT02113241 - Effect of Dapagliflozin Administration on Metabolic Syndrome, Insulin Sensitivity, and Insulin Secretion | Biotech Hunter | Biotech Hunter